A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2018
Price : $35 *
At a glance
- Drugs Gevokizumab (Primary)
- Indications Uveitis
- Focus Adverse reactions; Registrational
- Acronyms EYEGUARD-X
- Sponsors Servier
- 21 Oct 2015 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 12 Sep 2014 New trial record